Objective: To review the progress towards the goal of elimination of visceral leishmaniasis (Kala azar) from the Indian sub-continent by 2015.
INTRODUCTION:
Visceral Leishmaniasis (VL), also known as Kala azar or black fever, is a vector-borne parasitic disease. 1 Kala azar is one of the World's most neglected and poverty-related diseases, affecting the poorest people in developing countries associated with malnutrition, weakness of the immune system, displacement, poor housing, illiteracy, gender discrimination, and lack of resources. 2 Kala azar is spread over a large geographical area across the globe with estimated yearly incidence of Kala azar of 500,000 cases, which lead to loss of nearly 2.4 million disability-adjusted life years (DALYs) each year. 3 Since the last century several outbreaks of Kala azar have affected South-East Asia. Various programmes to control the disease have failed despite considerable efforts being done for prevention and control of the disease. 
WHY IS VISCERAL LEISHMANIASIS A CANDIDATE FOR ELIMINATION?
Currently several factors have made a smooth road for achieving the goal of eliminating Kala azar from the South East Asia Region(SEAR). 5 In SEAR, the only causative agent is protozoan parasite Leishmania Donovani, the only known vector is the female Sandfly of genus Phlebotomus Argentipes and the only reservoir is human. 
EPIDEMIOLOGY OF KALA AZAR:
Kala azar is endemic in 88 countries, particularly in Africa, Latin America, South and Central Asia, the Mediterranean basin and the Middle East with over 200 million people at risk. 2, 11 In the South-East Asian Region Kala azar is prevalent in India, Bangladesh and
Nepal and with few foci in Bhutan. 6 It is endemic in 115 districts spread over this four countries namely India (52), Bangladesh (45), Nepal (12) and Bhutan (6). 11 In India Kala azar cases are concentrated in Bihar, Uttar Pradesh, West Bengal and Jharkhand with over 165.4 million people at risk. 10 In India there is a resurgence of Kala azar in last few years, but overall deaths are declining. 10, 11 ( Figure 1 ) Epidemiologically, Kala azar follows an epidemic cycle resurging almost every 15-20 years. 12 The population at risk is nearly 65 million, 6 million, and 2.5 million in Bangladesh, Nepal and Bhutan respectively.
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Regardless of lots of strategy for elimination estimated annual incidence of Kala azar cases are varying from 20 -25 in India, 5 -8 in Nepal and 13 -31 in Bangladesh per 10,000 population. 
STEPS AND STRATEGIES TOWARDS ELIMINATION:
In India, first step that decreased the incidence of Kala azar was residual insecticide spray under National Malaria Control Programme in the year 1953 which lead to significant reduction in cases of Kala azar. 14 In Bangladesh Kala azar virtually disappeared during the 'Malaria Eradication Programme (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) marks the start of Consolidation phase for next three years followed by Maintenance phase of at least two to three years. 11 Signing of tripartite MoU by three countries commences the beginning of Preparatory phase. Main activities during this phase were pilot total spraying operation, establishment of diagnosis and treatment facilities in endemic countries, monitoring and planning. It is followed by the attack phase. The main activities during this phase included the indoor residual spraying in endemic areas, integrated vector management, early diagnosis and treatment, case detection, and vector surveillance, community mobilization, external country evaluation and building research capacity. Presently the consolidation phase has started for next three years. It is aimed to do active surveillance untill no increase in the incidence rate of Kala azar occurs at the district and sub district levels in endemic countries. Total coverage spraying is modified to limit indoor residual spraying in endemic areas. This will be followed by maintenance phase intending to do surveillance against reintroduction of Kala azar until Kala azar is no longer a public health problem. This will be verified by an international review commission followed by certification of the elimination status. 
CHALLENGES IN ELIMINATION:
The key indicators of Kala azar elimination are case detection rate, treatment completion rate, coverage rate for vector control and social mobilization. 20 The burden of Kala azar is grossly underestimated by the health systems in the Indian sub-continent due to over-reliability on passive surveillance. 21, 22 Though Kala azar patients ultimately report to health centers and hospitals, diagnosis is often missed in the early stages of infection and delayed due to lack of diagnostic facilities at peripheral levels of the health system with a consequent delay in treatment and sustaining the human reservoir. Besides this unavailability of noninvasive rapid diagnostic test aggravates the delay the diagnosis. 7 Many
Kala azar cases go undiagnosed in a web of unqualified medical practitioners which further adds to considerable delay in diagnosis and treatment. 23 Patients who are going to private sector for treatment usually stop in between due to high cost, leading to prolonged transmission. 18 Strategies are to improve reporting by strengthening diagnosis and treatment besides involving the private sector.
To give pace to the elimination, Kala azar could be addressed as notifiable disease. 24 This will not only help to estimate the true burden of Kala azar but also hasten the treatment of the patient provided with better monitoring. There is a wide gap in training and support of staff with technical and management expertise. As prevention and control activities for Kala azar are increasing in India, there is a need to strengthen the health system.
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The Poly-parasitism and co-infections are major emerging problems in world of Kala azar. In recent years, the threat of HIV and Kala azar co-infection is amplifying. To date, coinfection with leishmaniasis and HIV has reached 35 countries. The risk of developing Kala azar in endemic areas is about 100 to 1000 times higher in individuals infected with HIV.
HIV infection also impairs treatment response and increases the likelihood of recurrence. 25 If
HIV epidemic spreads to the general population where Kala azar is endemic, it may have disastrous consequences.
Resistance was reported for DDT indoor residual spraying and uses of insecticide treated nets are inconclusive, so there is a need to assess alternative vector control methods.
Governmental indoor residual spraying was not in operation in Bangladesh until year 2010 and sub optimum in India and Nepal in attack phase. 26 A research strategy is required to develop new methods for vector control considering air and water pollution, deforestation, habitat fragmentation, ecological disruption and changing agricultural practices, which have an impact on the incidence, prevalence and spread of infectious diseases. 24 Post Kala Azar Dermal Leishmaniasis (PKDL) patients have probably epidemiological importance in Kala azar transmission as the lesions can harbour a large amount of Leishmania parasites, and as such could constitute a reservoir in the community capable of triggering a new epidemic. 17 As PKDL causes little or no clinical discomfort, and PKDL treatment with intramuscular SSG injections is long (3-4 months), painful and cumbersome, few patients seek treatment.
A generic Miltefosine pharmaceutical product emerged in Bangladesh for the treatment of visceral leishmaniasis and use in the national elimination programme. Poorquality drugs for the treatment of this fatal neglected tropical disease are not only lifethreatening but also have a devastating impact on public health and elimination programme targeting this disease. 27 Kala azar patients belong to the poorest quintile of the population, which make them highly dependent for drug provision by National elimination programme.
These extremely vulnerable patients deserve to be protected by national or regional drug regulators who should take responsibility by implementing the necessary precautions to prevent poor-quality drugs. 27 Shortage and supply delays of Kala azar drugs, unavailability of diagnostics at the health center level often contributes to the community's poor public perception of the public health systems and as consequent low community participation in Kala azar control program activities. 8, 28 Production of medicines for neglected tropical diseases ought to become attractive to manufacturers of generic drugs. India and Nepal respectively. 13 Supports from International agencies and Non-Governmental organization need to be achieved to overcome the economic constrains.
FUTURE COURSE TOWARDS ELIMINATION:
To combat the problem of treatment failure in Kala azar and to reduce the length of therapy, combination of at least two effective anti leishmanial agents is a need to be assessed. 17 hoardings and other along with electronic media will prove to be a powerful tool for this.
Public-private partnership and involvement of NGOs need to be strengthened in order to provide better services to Kala azar patients. Public Private Partnership is essential to boost funding and support. Political commitment and development of accountability is the need of the hour. Though three endemic countries have three more years to achieve the set targets, but it is still far off the expectation.
